Research programme: recombinant apolipoprotein AI - SemBioSys Genetics

Drug Profile

Research programme: recombinant apolipoprotein AI - SemBioSys Genetics

Alternative Names: Apolipoprotein AI - SemBioSys Genetics; Apolipoprotein AI(Milano) - SemBioSys Genetics; Plant-derived apolipoprotein AI - SemBioSys Genetics

Latest Information Update: 04 May 2012

Price : $50

At a glance

  • Originator SemBioSys Genetics
  • Class Apolipoprotein therapeutics; Recombinant proteins
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • Available For Licensing Yes - Cardiovascular disorders

Highest Development Phases

  • Discontinued Acute coronary syndromes; Atherosclerosis; Cardiovascular disorders; Stroke

Most Recent Events

  • 30 Apr 2012 Discontinued - Preclinical for Stroke in Canada (Parenteral)
  • 30 Apr 2012 Discontinued - Preclinical for Cardiovascular disorders in Canada (Parenteral)
  • 30 Apr 2012 Discontinued - Preclinical for Atherosclerosis in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top